Cargando…

CSF metabolites associated with biomarkers of Alzheimer’s disease pathology

INTRODUCTION: Metabolomics technology facilitates studying associations between small molecules and disease processes. Correlating metabolites in cerebrospinal fluid (CSF) with Alzheimer’s disease (AD) CSF biomarkers may elucidate additional changes that are associated with early AD pathology and en...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Ruocheng, Lu, Qiongshi, Kang, Hyunseung, Suridjan, Ivonne, Kollmorgen, Gwendlyn, Wild, Norbert, Deming, Yuetiva, Van Hulle, Carol A., Anderson, Rozalyn M., Zetterberg, Henrik, Blennow, Kaj, Carlsson, Cynthia M., Asthana, Sanjay, Johnson, Sterling C., Engelman, Corinne D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499619/
https://www.ncbi.nlm.nih.gov/pubmed/37719875
http://dx.doi.org/10.3389/fnagi.2023.1214932
_version_ 1785105748889436160
author Dong, Ruocheng
Lu, Qiongshi
Kang, Hyunseung
Suridjan, Ivonne
Kollmorgen, Gwendlyn
Wild, Norbert
Deming, Yuetiva
Van Hulle, Carol A.
Anderson, Rozalyn M.
Zetterberg, Henrik
Blennow, Kaj
Carlsson, Cynthia M.
Asthana, Sanjay
Johnson, Sterling C.
Engelman, Corinne D.
author_facet Dong, Ruocheng
Lu, Qiongshi
Kang, Hyunseung
Suridjan, Ivonne
Kollmorgen, Gwendlyn
Wild, Norbert
Deming, Yuetiva
Van Hulle, Carol A.
Anderson, Rozalyn M.
Zetterberg, Henrik
Blennow, Kaj
Carlsson, Cynthia M.
Asthana, Sanjay
Johnson, Sterling C.
Engelman, Corinne D.
author_sort Dong, Ruocheng
collection PubMed
description INTRODUCTION: Metabolomics technology facilitates studying associations between small molecules and disease processes. Correlating metabolites in cerebrospinal fluid (CSF) with Alzheimer’s disease (AD) CSF biomarkers may elucidate additional changes that are associated with early AD pathology and enhance our knowledge of the disease. METHODS: The relative abundance of untargeted metabolites was assessed in 161 individuals from the Wisconsin Registry for Alzheimer’s Prevention. A metabolome-wide association study (MWAS) was conducted between 269 CSF metabolites and protein biomarkers reflecting brain amyloidosis, tau pathology, neuronal and synaptic degeneration, and astrocyte or microglial activation and neuroinflammation. Linear mixed-effects regression analyses were performed with random intercepts for sample relatedness and repeated measurements and fixed effects for age, sex, and years of education. The metabolome-wide significance was determined by a false discovery rate threshold of 0.05. The significant metabolites were replicated in 154 independent individuals from then Wisconsin Alzheimer’s Disease Research Center. Mendelian randomization was performed using genome-wide significant single nucleotide polymorphisms from a CSF metabolites genome-wide association study. RESULTS: Metabolome-wide association study results showed several significantly associated metabolites for all the biomarkers except Aβ42/40 and IL-6. Genetic variants associated with metabolites and Mendelian randomization analysis provided evidence for a causal association of metabolites for soluble triggering receptor expressed on myeloid cells 2 (sTREM2), amyloid β (Aβ40), α-synuclein, total tau, phosphorylated tau, and neurogranin, for example, palmitoyl sphingomyelin (d18:1/16:0) for sTREM2, and erythritol for Aβ40 and α-synuclein. DISCUSSION: This study provides evidence that CSF metabolites are associated with AD-related pathology, and many of these associations may be causal.
format Online
Article
Text
id pubmed-10499619
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104996192023-09-15 CSF metabolites associated with biomarkers of Alzheimer’s disease pathology Dong, Ruocheng Lu, Qiongshi Kang, Hyunseung Suridjan, Ivonne Kollmorgen, Gwendlyn Wild, Norbert Deming, Yuetiva Van Hulle, Carol A. Anderson, Rozalyn M. Zetterberg, Henrik Blennow, Kaj Carlsson, Cynthia M. Asthana, Sanjay Johnson, Sterling C. Engelman, Corinne D. Front Aging Neurosci Neuroscience INTRODUCTION: Metabolomics technology facilitates studying associations between small molecules and disease processes. Correlating metabolites in cerebrospinal fluid (CSF) with Alzheimer’s disease (AD) CSF biomarkers may elucidate additional changes that are associated with early AD pathology and enhance our knowledge of the disease. METHODS: The relative abundance of untargeted metabolites was assessed in 161 individuals from the Wisconsin Registry for Alzheimer’s Prevention. A metabolome-wide association study (MWAS) was conducted between 269 CSF metabolites and protein biomarkers reflecting brain amyloidosis, tau pathology, neuronal and synaptic degeneration, and astrocyte or microglial activation and neuroinflammation. Linear mixed-effects regression analyses were performed with random intercepts for sample relatedness and repeated measurements and fixed effects for age, sex, and years of education. The metabolome-wide significance was determined by a false discovery rate threshold of 0.05. The significant metabolites were replicated in 154 independent individuals from then Wisconsin Alzheimer’s Disease Research Center. Mendelian randomization was performed using genome-wide significant single nucleotide polymorphisms from a CSF metabolites genome-wide association study. RESULTS: Metabolome-wide association study results showed several significantly associated metabolites for all the biomarkers except Aβ42/40 and IL-6. Genetic variants associated with metabolites and Mendelian randomization analysis provided evidence for a causal association of metabolites for soluble triggering receptor expressed on myeloid cells 2 (sTREM2), amyloid β (Aβ40), α-synuclein, total tau, phosphorylated tau, and neurogranin, for example, palmitoyl sphingomyelin (d18:1/16:0) for sTREM2, and erythritol for Aβ40 and α-synuclein. DISCUSSION: This study provides evidence that CSF metabolites are associated with AD-related pathology, and many of these associations may be causal. Frontiers Media S.A. 2023-08-30 /pmc/articles/PMC10499619/ /pubmed/37719875 http://dx.doi.org/10.3389/fnagi.2023.1214932 Text en Copyright © 2023 Dong, Lu, Kang, Suridjan, Kollmorgen, Wild, Deming, Van Hulle, Anderson, Zetterberg, Blennow, Carlsson, Asthana, Johnson and Engelman. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Dong, Ruocheng
Lu, Qiongshi
Kang, Hyunseung
Suridjan, Ivonne
Kollmorgen, Gwendlyn
Wild, Norbert
Deming, Yuetiva
Van Hulle, Carol A.
Anderson, Rozalyn M.
Zetterberg, Henrik
Blennow, Kaj
Carlsson, Cynthia M.
Asthana, Sanjay
Johnson, Sterling C.
Engelman, Corinne D.
CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
title CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
title_full CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
title_fullStr CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
title_full_unstemmed CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
title_short CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
title_sort csf metabolites associated with biomarkers of alzheimer’s disease pathology
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499619/
https://www.ncbi.nlm.nih.gov/pubmed/37719875
http://dx.doi.org/10.3389/fnagi.2023.1214932
work_keys_str_mv AT dongruocheng csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT luqiongshi csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT kanghyunseung csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT suridjanivonne csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT kollmorgengwendlyn csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT wildnorbert csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT demingyuetiva csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT vanhullecarola csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT andersonrozalynm csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT zetterberghenrik csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT blennowkaj csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT carlssoncynthiam csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT asthanasanjay csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT johnsonsterlingc csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology
AT engelmancorinned csfmetabolitesassociatedwithbiomarkersofalzheimersdiseasepathology